A minireview of pharmacotherapy of type 2 diabetes – drugs and mechanisms
DOI:
https://doi.org/10.33448/rsd-v11i12.34900Keywords:
Diabetes Mellitus; Glycemic Control; Hypoglycemic agents.Abstract
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder that originates from numerous pathogenic mechanisms, all of which result in hyperglycemia. This disease is a major cause of morbidity and mortality worldwide. Effective prevention and treatment strategies for T2DM are therefore necessary. The purpose of this review was to summarize the pharmacotherapy for patients with T2DM by discussing its pathophysiology, the therapeutic classes used in treatment strategies, as well as the mechanisms of action for each one. A literature review was conducted by searching Google Scholar, PubMed, and Science Direct databases using the search terms: type 2 diabetes mellitus, insulin, AMPK, antidiabetic drugs, incretin, SGLT2, and biguanides covering studies up to 2022. The review identified and included studies including qualitative, original research articles, and randomized controlled trial designs. The results of this study are divided into drugs that increase insulin sensitivity (e.g., biguanides, and thiazolidinediones), secretagogues (e.g., sulfonylureas, and meglitinides or glinides), incretin mimetics drugs (e.g., GLP-1 receptor agonists, and DPP-4 inhibitors), drugs that cause glycosuria (e.g., SGLT2 inhibitors), drugs that prevent glucose absorption (e.g., α-glucosidase inhibitor), and insulin. This allows the readers to understand each process while keeping the paper concise.
References
Alexander, J. T, Staab, E. M, Wan, W. et al (2022). Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: a Systematic Review and Meta-analysis. Journal of General Internal Medicine, 37, 439–448. Doi: 10.1007/s11606-021-07227-0.
Aslam, M., & Ladilov, L. (2022). Emerging Role of cAMP/AMPK Signaling. Cells, 11(2), 308. Doi: 10.3390/cells11020308.
Chandra, A., Kaur, P, Sahu, S. K., & Mittal, A. (2022). A new insight into the treatment of diabetes by means of pan PPAR agonists. Chem Biol Drug Des, 1–21. Doi: https://doi.org/10.1111/cbdd.14020.
Dawwas, G. K., Flory, J. H., Hennessy, S, Leonard, C. E., & Lewis, J. D. (2022). Comparative Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis. Diabetes Care, 45, (4), 919–927. Doi: https://doi.org/10.2337/dc21-2177.
Deng, K., & Thorn, P. (2022). Presynaptic-like mechanisms and the control of insulin secretion in pancreatic β-cells. Cell Calcium,104,102585. Doi: 10.1016/j.ceca.2022.102585.
Fralick, M, Jenkins, A. J, Khunti, K., et al. (2022). Global accessibility of therapeutics for diabetes mellitus. Nature Reviews Endocrinology, 18, 199–204. DOI: 10.1038/s41574-021-00621-y
González-González, J. G., et al. (2022). Effect of metformin on microvascular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 186, 109821. Doi.org/10.1016/j.diabres.2022.109821
Hanefeld, M, Cagatay, M, Petrowitsch, T, Neuser, D, Petzinna, D, & Rupp, M. (2004). Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J, 25, (1), 10–6. Doi:10.1016/S0195-668X(03)00468-8
Haq, F. U, Siraj, A, Ameer, M. A, et al. (2021). Comparative Review of Drugs Used in Diabetes Mellitus—New and Old. Journal of Diabetes Mellitus, 11, (4). Doi: 10.4236/jdm.2021.114009
Hasanvand, A. (2022). The role of AMPK-dependent pathways in cellular and molecular mechanisms of metformin: a new perspective for treatment and prevention of diseases. Inflammopharmacology, 30, 775–788. DOI: 10.1007/s10787-022-00980-6
Inzucchi, S. E, Bergenstal, R. M, Buse, J. B, et al. (2015). Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 38, (1), 140–9. Doi.org/10.2337/dc14-2441
Irudayaraj, S. S, Jincy, J, Sunil, C, et al. (2022). Antidiabetic with antilipidemic and antioxidant effects of flindersine by enhanced glucose uptake through GLUT4 translocation and PPARγ agonism in type 2 diabetic rats. Journal of Ethnopharmacology, 285, 114883. Doi.org/10.1016/j.jep.2021.114883
Klip, A, McGraw, T. E., & James, D. E. (2019). Thirty sweet years of GLUT4. J. Biol. Chem, 294, 11369-11381. Doi: 10.1074/jbc.REV119.008351
Knudsen, J. R, Steenberg, D. E, Hingst, J. R et al. (2020). Prior exercise in humans redistributes intramuscular GLUT4 and enhances insulin-stimulated sarcolemmal and endosomal GLUT4 translocation. Mol. Metab, 39,100998. Doi: 10.1016/j.molmet.2020.100998
Ku, E. J, Lee, D. H, Jeon, H. J & Oh, TK. (2021). Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study. Diabetes Research and Clinical Practice, 182, 109123. Doi: 10.1016/j.diabres.2021.109123
Lavania, P. (2019). A comparative study of glimepiride plus metformin versus glibenclamide plus metformin in diabetes mellitus patients. Journal of Advanced Medical and Dental Sciences Research, 7, (2), 157-160. Doi: 10.21276/jamdsr
Lin, EE, Scott-Solomon, E & Kuruvilla, R. (2021). Peripheral Innervation in the Regulation of Glucose Homeostasis. Trends in Neurosciences, 44, (3), 189-202. Doi: 10.1016/j.tins.2020.10.015
Lingvay, I, Bauer, R, Baker-Knight, J, Lawson, J & Pratley, R. (2022). An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression. The Journal of Clinical Endocrinology & Metabolism, 107, (5), 1461–1469. Doi: 10.1210/clinem/dgab905
Min, SH, Yoon, JH, Hahn, S & Cho, YM. (2018). Efficacy and safety of combination therapy with an α-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta-analysis. J Diabetes Investig, 9, (4), 893-902. Doi: 10.1111/jdi.12754
Mone, P, Varzideh, F, Jankauskas, SS, et al. (2022). SGLT2 inhibition via empagliflozin improves endothelial function and reduces mitochondrial oxidative stress: insights from frail hypertensive and diabetic patients. Hypertension,79, (8), 1633–1643. Doi: 10.1161/HYPERTENSIONAHA.122.19586
Peng, F, Li, X, Xiao, F, Zhao, R & Sun, Z. (2022). Circadian clock, diurnal glucose metabolic rhythm, and dawn phenomenon. Trends in Neurosciences, 45, (6), 471-482. Doi.org/10.1016/j.tins.2022.03.010
Pullen, RA, Lindsay, DG, Wood, SP, Tickle, IJ et al. (1976). Receptor-binding region of insulin. Nature, 259, 369-373.
Saltiel, AR. (2021). Insulin signaling in health and disease. J Clin Invest,131, (1), e142241. Doi: 10.1172/JCI142241
Scheen, AJ. (2021). Sulphonylureas in the management of type 2 diabetes: To be or not to be? Diabetes Epidemiology and Management, 1, 100002. Doi.org/10.1016/j.deman.2021.100002
Shyng, SL. (2022). KATP Channel Function: More than Meets the Eye. Function, 3, (1), zqab070. Doi.org/10.1093/function/zqab070
Svitlana, D, Kateryna, K, Iryna, B, et al. (2021). Potential risks and pharmacological safety features of hypoglycemic drugs. Archives, 2, 1164-1171.
Sylow, L, Tokarz, VL, Richter, EA & Klip, A. (2021). The many actions of insulin in skeletal muscle, the paramount tissue determining glycemia. Cell Metabolism, 33, (4), 758-780. Doi: 10.1016/j.cmet.2021.03.020
Tomlinson, B, Patil, NG, Fok, M, Chan, P & Lam, CWK. (2022). The role of sulfonylureas in the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy,23, (3), 387-403. Doi.org/10.1080/14656566.2021.1999413
Verberne, AJM & Mussa, BM. (2022). Neural control of pancreatic peptide hormone secretion. Peptides, 152, 70768. Doi.org/10.1016/j.peptides.2022.170768
Wei, Y, Lin, F, Lin, S & Wang, C. (2018). Concomitant use of Repaglinide and Clopidogrel and risk of hypoglycemia: a population-based nested case-control study. Value in Health, 21, S1–S115. Doi.org/10.1016/j.jval.2018.07.276
Wharton, S, Davies, M, Dicker, D, et al. (2021). Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate Medicine, 134, (1), 14-19. Doi: 10.1080/00325481.2021.2002616
Yau H, Rivera K, Lomonaco R & Cusi K. (2013). The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. Curr Diab Rep,13, (3), 329-41.
Zhang, Y, Fu, T, Mu, YM, et al. (2021). Network Meta-analysis of the Therapeutic Effects of Hypoglycemic Drugs and Intensive Lifestyle Modification on Impaired Glucose Tolerance. Clinical Therapeutics, 43, (9), 1524-1556. Doi: 10.1016/j.clinthera.2021.07.014
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Erick Bryan de Sousa Lima; Ana Caroline Ventris de Godoy; Simone de Araújo
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
